Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration
Acta Ophthalmologica Jul 16, 2019
Aurell S, et al. - In eyes with neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor injections, researchers assessed treatment outcome at 12 months in relation to pro re nata (PRN)- or treat-and-extend (TE)-regimen, in one clinical setting in Sweden. Overall 443 eyes including 223 PRN- and 220 TE-treated eyes were included in this study. Findings revealed better visual outcome at 12 months in eyes treated according to TE. In clinical routine care of nAMD, the superiority of treatment according to proactive TE-regimen, compared with treatment according to PRN-regimen, is suggested.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries